Povetacicept is designed to reduce the inflammation and harmful antibodies that destroy red blood cells in cold agglutinin disease, which may improve anemia.
Investigational means that povetacicept is still being evaluated and is not approved by any health authority (e.g., the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA)).
Additional information is available at RUBY-4 ClinicalTrials.gov.